| Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake A Marin, H Sun, GA Husseini, WG Pitt, DA Christensen, NY Rapoport Journal of controlled release 84 (1), 39-47, 2002 | 263 | 2002 |
| Drug delivery in polymeric micelles: from in vitro to in vivo N Rapoport, WG Pitt, H Sun, JL Nelson Journal of controlled release 91 (1), 85-95, 2003 | 233 | 2003 |
| Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks STM Orr, SL Ripp, TE Ballard, JL Henderson, DO Scott, RS Obach, H Sun, ... Journal of Medicinal Chemistry 55 (11), 4896-4933, 2012 | 212 | 2012 |
| Structure‐based Drug Metabolism Predictions for Drug Design H Sun, DO Scott Chemical biology & drug design 75 (1), 3-17, 2010 | 167 | 2010 |
| Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors AF Stepan, K Karki, WS McDonald, PH Dorff, JK Dutra, KJ DiRico, A Won, ... Journal of medicinal chemistry, 2011 | 97 | 2011 |
| Metabolic activation of a novel 3-substituted indole-containing TNF-α inhibitor: dehydrogenation and inactivation of CYP3A4 H Sun, GS Yost Chemical research in toxicology 21 (2), 374-385, 2007 | 54 | 2007 |
| Structure-activity relationship of capsaicin analogs and transient receptor potential vanilloid 1-mediated human lung epithelial cell toxicity KC Thomas, M Ethirajan, K Shahrokh, H Sun, J Lee, TE Cheatham III, ... Journal of Pharmacology and Experimental Therapeutics 337 (2), 400-410, 2011 | 53 | 2011 |
| Metabolism of 4-aminopiperidine drugs by cytochrome P450s: molecular and quantum mechanical insights into drug design H Sun, DO Scott ACS Medicinal Chemistry Letters, 2011 | 51 | 2011 |
| Bioavailability, biotransformation, and excretion of the covalent bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans T Podoll, PG Pearson, J Evarts, T Ingallinera, E Bibikova, H Sun, ... Drug Metabolism and Disposition 47 (2), 145-154, 2019 | 48 | 2019 |
| Dehydrogenation of indoline by cytochrome P450 enzymes: a novel “aromatase” process H Sun, WJ Ehlhardt, P Kulanthaivel, DL Lanza, CA Reilly, GS Yost Journal of Pharmacology and Experimental Therapeutics 322 (2), 843-851, 2007 | 45 | 2007 |
| Effect of Structural Variation on Aldehyde Oxidase-Catalyzed Oxidation of Zoniporide D Dalvie, H Sun, C Xiang, Q Hu, Y Jiang, P Kang Drug Metabolism and Disposition 40 (8), 1575-1587, 2012 | 40 | 2012 |
| Systematic and Pairwise Analysis of the Effects of Aromatic Halogenation and Trifluoromethyl Substitution on Human Liver Microsomal Clearance H Sun, C E Keefer, D O Scott Drug Metabolism Letters 5 (4), 232-242, 2011 | 34 | 2011 |
| Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions H Sun, C Moore, PM Dansette, S Kumar, JR Halpert, GS Yost Drug Metabolism and Disposition 37 (3), 672-684, 2009 | 32 | 2009 |
| Metabolism, Excretion, and Pharmacokinetics of ((3, 3-difluoropyrrolidin-1-yl)((2S, 4S)-4-(4-(pyrimidin-2-yl) piperazin-1-yl) pyrrolidin-2-yl) methanone, a DPP-IV Inhibitor, in … R Sharma, H Sun, DW Piotrowski, TF Ryder, SD Doran, H Dai, C Prakash Drug Metabolism and Disposition, dmd. 112.047316, 2012 | 30 | 2012 |
| Discovery Tactics To Mitigate Toxicity Risks Due to Reactive Metabolite Formation with 2-(2-Hydroxyaryl)-5-(trifluoromethyl) pyrido [4, 3-d] pyrimidin-4 (3 H)-one Derivatives … AS Kalgutkar, DA Griffith, T Ryder, H Sun, Z Miao, JN Bauman, MT Didiuk, ... Chemical research in toxicology 23 (6), 1115-1126, 2010 | 27 | 2010 |
| Discovery of selective small molecule inhibitors of monoacylglycerol acyltransferase 3 K Huard, AT Londregan, G Tesz, KB Bahnck, TV Magee, D Hepworth, ... Journal of medicinal chemistry 58 (18), 7164-7172, 2015 | 16 | 2015 |
| Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics H Sun, DO Scott Chemico-Biological Interactions, 2011 | 16 | 2011 |
| Differences in CYP3A4 catalyzed bioactivation of 5-aminooxindole and 5-aminobenzsultam scaffolds in proline-rich tyrosine kinase 2 (PYK2) inhibitors: Retrospective analysis by … H Sun, R Sharma, J Bauman, DP Walker, GE Aspnes, MP Zawistoski, ... Bioorganic & medicinal chemistry letters 19 (12), 3177-3182, 2009 | 16 | 2009 |
| Single Mutations Change CYP2F3 From a Dehydrogenase of 3-Methylindole to an Oxygenase† JS Kartha, KW Skordos, H Sun, C Hall, LHM Easterwood, CA Reilly, ... Biochemistry 47 (37), 9756-9770, 2008 | 16 | 2008 |
| Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism H Sun, AJ Bessire, A Vaz Bioorganic & medicinal chemistry letters, 2011 | 15 | 2011 |
